A Pilot Study to Evaluate Barhemsys for the Prevention of Postoperative Nausea and Vomiting in the Bariatric Surgery Population
Launched by BENAROYA RESEARCH INSTITUTE · Sep 3, 2024
Trial Information
Current as of July 09, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a medication called Barhemsys to see if it can help prevent nausea and vomiting after bariatric surgery, which is a type of weight loss surgery. Researchers want to find out how effective Barhemsys is for patients who might experience these uncomfortable symptoms after their surgery. The study is currently looking for adult participants aged 18 to 65 who are scheduled for specific types of bariatric surgery and will be staying in the hospital for at least one day after their procedure.
To be eligible for the trial, participants should be in good general health (ASA class I-III) and not have certain medical conditions, such as pregnancy, severe kidney issues, or allergies to Barhemsys. Those who take specific medications or have certain health concerns, like Parkinson's disease, will not be able to join. If you participate, you can expect to receive the study medication during your hospital stay and be monitored for any side effects or improvements in your symptoms. This trial aims to improve care for patients undergoing bariatric surgery by reducing the risk of postoperative nausea and vomiting.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • The study will recruit adult patients (Age 18-65) scheduled for bariatric surgery. Additional inclusion criteria include ASA class I-III and patients who plan to be inpatient for at least 24 hours.
- Included Surgeries:
- • Robotic, Laparoscopic or Open Roux-en-Y Robotic, Laparoscopic or Open Gastric Sleeve Robotic, Laparoscopic or Open Gastrectomy Robotic, Laparoscopic or Open Revision Gastric Bypass
- Exclusion Criteria:
- • Pregnant or breastfeeding
- • Presence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the patient or the quality of the data.
- • Congenital QTc abnormalities
- • Current use of droperidol
- • Parkinson's disease
- • Allergy to Barhemsys
- • GFR \< 30 mL/min/1.73m2
- • Emergency surgery or add-on cases
About Benaroya Research Institute
Benaroya Research Institute (BRI) is a leading nonprofit research organization dedicated to advancing the understanding and treatment of autoimmune diseases, including type 1 diabetes and rheumatoid arthritis. Situated in Seattle, Washington, BRI is renowned for its innovative approach that integrates cutting-edge research, patient care, and clinical trials. The institute fosters collaboration among scientists, clinicians, and patients to translate scientific discoveries into effective therapies. Through its commitment to excellence in research and education, BRI aims to significantly improve patient outcomes and contribute to the global fight against autoimmune disorders.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Seattle, Washington, United States
Patients applied
Trial Officials
Justin S Liberman, Medical Doctor
Principal Investigator
Virginia Mason Medical Center
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported